Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders.

Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29

Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol (2000) 1.39

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia. Leukemia (2012) 1.21

Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem (2013) 0.84

T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Clin Exp Immunol (2006) 0.79

High-resolution record of Northern Hemisphere climate extending into the last interglacial period. Nature (2004) 6.44

Serum levels of cytokines in chronic liver diseases. Gastroenterology (1992) 3.47

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31

A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49

Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99

T cell assays and MIATA: the essential minimum for maximum impact. Immunity (2012) 1.74

Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res (2001) 1.66

The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol (1981) 1.53

Sulphate transporter gene mutations in apparently isolated club foot. J Med Genet (2001) 1.47

Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation (1983) 1.47

Aniline blue staining as a marker of sperm chromatin defects associated with different semen characteristics discriminates between proven fertile and suspected infertile men. Int J Androl (1990) 1.46

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia (2007) 1.43

Further evidence for lymphokine overproduction in severe aplastic anemia. Blood (1988) 1.43

Effectiveness of intraocular lens calculation in high ametropia. J Cataract Refract Surg (1989) 1.42

Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood (1996) 1.41

Epidural butorphanol does not reduce side effects from epidural morphine after cesarean birth. Anesth Analg (1994) 1.39

Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol (1992) 1.37

Human autologous mixed lymphocyte reactivity is primarily specific for xenoprotein determinants adsorbed to antigen-presenting cells during rosette formation with sheep erythrocytes. J Exp Med (1982) 1.37

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2010) 1.36

Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol (1983) 1.34

Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood (2000) 1.29

State dependent dissociation of HERG channel inhibitors. Br J Pharmacol (2007) 1.27

Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 1.25

The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med (1998) 1.22

Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos (1998) 1.20

Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation (1990) 1.18

Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res (1998) 1.17

Liver transplantation followed by high-dose cyclophosphamide, total-body irradiation, and autologous bone marrow transplantation for treatment of metastatic breast cancer. A case report. Transplantation (1984) 1.16

Biosynthesis and metabolism of pterins in peripheral blood mononuclear cells and leukemia lines of man and mouse. Eur J Biochem (1987) 1.15

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol (1995) 1.14

Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med (1990) 1.14

Analysis of the structure-function relationship of the S-layer protein SbsC of Bacillus stearothermophilus ATCC 12980 by producing truncated forms. Microbiology (2001) 1.14

Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome (AIDS). A preliminary report. Hoppe Seylers Z Physiol Chem (1983) 1.14

Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther (2010) 1.14

Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol (1993) 1.13

Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol (2001) 1.13

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant (2005) 1.13

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer (2003) 1.12

The chronology of third molar mineralization in the Austrian population--a contribution to forensic age estimation. Forensic Sci Int (2006) 1.11

Interferon-gamma enhances biosynthesis of pterins in peripheral blood mononuclear cells by induction of GTP-cyclohydrolase I activity. J Interferon Res (1986) 1.11

Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res (1999) 1.10

Zinc deficiency and zinc repletion: effect on the response of rats to infection with Trichinella spiralis. Am J Clin Nutr (1990) 1.09

Planned myopic astigmatism as a substitute for accommodation in pseudophakia. J Am Intraocul Implant Soc (1981) 1.08

Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol (1998) 1.07

Cyclosporin blood levels do correlate with clinical complications. Lancet (1984) 1.07

Combined liver and kidney transplantation. Lancet (1984) 1.07

IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol (1988) 1.06

Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol (2001) 1.04

Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera. Br J Haematol (1994) 1.03

Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant (2006) 1.03

Isoalloxazine derivatives promote photocleavage of natural RNAs at G.U base pairs embedded within helices. Nucleic Acids Res (1997) 1.03

Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemost (1997) 1.02

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther (2011) 1.01

The human immunoglobulin kappa locus. Characterization of the duplicated A regions. Eur J Immunol (1992) 1.01

Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation (1984) 1.01

Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol (2001) 1.01

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway. Oncogene (2009) 1.01

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer (2000) 1.00

SHOX point mutations in dyschondrosteosis. J Med Genet (2001) 1.00

Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood (1993) 0.99

Human interferon-gamma induces expression of HLA-DR on keratinocytes and melanocytes. Arch Dermatol Res (1985) 0.99

Cytokines in the control of beta-2 microglobulin release. I. In vitro studies on various haemopoietic cells. Immunobiology (1988) 0.98

Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation (1990) 0.98

A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther (1998) 0.98

Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol (1996) 0.98

Quality indicators for the prevention of type 2 diabetes in Europe--IMAGE. Horm Metab Res (2010) 0.97

The RNA-binding properties of SMN: deletion analysis of the zebrafish orthologue defines domains conserved in evolution. Hum Mol Genet (1999) 0.96

Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol (1987) 0.96

[Properties and subcellular localization of newly synthesized proteins of human lymphocytes in vitro with and without the addition of phytohemagglutinin]. Klin Wochenschr (1967) 0.96

Purification and some properties of the tungsten-containing carboxylic acid reductase from Clostridium formicoaceticum. Biol Chem Hoppe Seyler (1991) 0.96

The influence of mechanical stimulation on osteocyte apoptosis and bone viability in human trabecular bone. J Musculoskelet Neuronal Interact (2006) 0.96

Three-dimensional representations of corneal deformations from keratotopography data. J Cataract Refract Surg (1997) 0.96

Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood (1994) 0.96

Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. Cancer Res (2001) 0.95

The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. Hum Mol Genet (1998) 0.95

Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft. Transplantation (1987) 0.95

Surface receptors on human haematopoietic cell lines. Clin Exp Immunol (1976) 0.95

Receptor sites for aggregated gammaglobulin (AGG) on lymphocytes in lymphoproliferative diseases. Br J Haematol (1974) 0.94

Release of interleukin 2 and gamma interferon by peripheral mononuclear cells in human Schistosoma mansoni infection normalizes after chemotherapy. Scand J Immunol (1989) 0.94

Mutations in cytokine receptor-like factor 1 (CRLF1) account for both Crisponi and cold-induced sweating syndromes. Am J Hum Genet (2007) 0.94

[Classification of lympho-proliferative diseases using lymphocyte tracers]. Verh Dtsch Ges Inn Med (1975) 0.94

Immune response modulation by pentoxifylline in vitro. Transplantation (1993) 0.94

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol (1989) 0.93

Linear density gradient separation of human lymphocyte subsets. I. Analysis by mixed leukocyte culture and cell-mediated lympholysis responses. Eur J Immunol (1977) 0.93

Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res (1996) 0.93

Lens implantation combined with trabeculectomy. Trans Ophthalmol Soc U K (1985) 0.93

Prospective long-term follow-up of the cementless bicontact hip stem with plasmapore coating. Z Orthop Unfall (2007) 0.93

Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens (2000) 0.93

Capillary zone electrophoresis and micellar electrokinetic chromatography of 4-aminobenzonitrile carbohydrate derivatives. Electrophoresis (1994) 0.92

Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant (1997) 0.92

Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. Blood (2001) 0.92

Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo. Cell Death Differ (2005) 0.92